Richard Puschinsky, MD
Urology · High Point, NCNPI 1245391085
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,049 of the $6,017 with a category attached, or 83.9%. It is spread thinly across 27 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,375 and has fallen 62.4% since, to $516 in 2025.
Across 272 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$925
- Astellas Pharma US Inc$893
- Endo Pharmaceuticals Inc.$724
- Procept Biorobotics Corporation$535
- Sumitomo Pharma America, Inc.$388
- Antares Pharma, Inc.$362
- plus $2K from 21 others
Across 17 payments — averaging $3271.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ferring International Pharmascience Center US$40K
- Ferring Pharmaceuticals AS$15K
- Sumitomo Pharma America, Inc.$1K
What the payments were for
- Travel & lodging$71512%
- Food & beverage$5,04984%
- Education$2534%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 16 | $925 |
| Astellas Pharma US Inc | 41 | $893 |
| Endo Pharmaceuticals Inc. | 49 | $724 |
| Procept Biorobotics Corporation | 5 | $535 |
| Sumitomo Pharma America, Inc. | 18 | $388 |
| Antares Pharma, Inc. | 17 | $362 |
| AbbVie | 25 | $356 |
| Myovant Sciences Inc. | 14 | $270 |
| Endo USA, Inc. | 15 | $260 |
| Johnson & Johnson | 15 | $200 |
| Pfizer | 8 | $132 |
| Urovant Sciences Inc | 8 | $115 |
| Axonics, Inc. | 5 | $109 |
| Coloplast | 5 | $106 |
| Urogen Pharma, Inc. | 4 | $105 |
| Medtronic(2 entities) | 4 | $99 |
| Halozyme Inc | 5 | $90 |
| Boston Scientific | 4 | $88 |
| Olympus America Inc. | 3 | $61 |
| ABC Home Medical Supply, Inc. | 2 | $46 |
| Laborie Medical Technologies Corp. | 2 | $33 |
| Teleflex Medical Incorporated | 2 | $31 |
| Merck | 1 | $23 |
| Myriad Genetic Laboratories, Inc. | 1 | $18 |
| Acerus Pharmaceuticals Corporation | 1 | $17 |
| Bayer | 1 | $16 |
| Tolmar Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$439
- UroLift System$433
How this compares
$6,017 in reported general payments places this provider in the 70th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 111 | $78,737 |
| OrgovyxRelugolix | 22 | $59,404 |
| GemtesaVibegron | 47 | $50,549 |
| Estradiol | 104 | $6,008 |
| Tamsulosin Hcl | 529 | $5,415 |
| Testosterone | 24 | $3,358 |
| Silodosin | 17 | $1,846 |
| Solifenacin Succinate | 31 | $1,434 |
| Cefdinir | 86 | $1,352 |
| Finasteride | 61 | $968 |
| Testosterone Cypionate | 38 | $896 |
| Ciprofloxacin Hcl | 97 | $819 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 28 | $578 |
| Ondansetron OdtOndansetron | 26 | $558 |
| Methenamine Hippurate | 13 | $536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $388 | $109,95369 claims |
| Astellas Pharma US IncMyrbetriq | $893 | $78,737111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 434 urology providers in North Carolina.
Other urology in High Point
- Robert LippittSmithfield$11.4M
- Michael KennellyCharlotte$1.3M
- John KasparRaleigh$1.1M
- Judd MoulDurham$1M
- Daniel GeorgeDurham$1M
- Scott MacdiarmidGreensboro$774K
- Glenn PremingerDurham$736K
- Michael LipkinDurham$293K
- Culley CarsonChapel Hill$275K
- Aaron LentzRaleigh$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.